SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.

Abstract:

:It is unclear which patients with breast cancer benefit from anthracycline-based neoadjuvant chemotherapy and whether taxanes increase survival. Hsp70 and serpinB3 inhibit a lysosomal cell death pathway induced in anthracycline and taxane treated cells, which may be critical for breast cancer cell survival. Thus we evaluated serpinB3 and Hsp70 as putative prognostic biomarkers in breast cancer patients treated with neoadjuvant chemotherapy. SerpinB3 and Hsp70 were measured by immunohistochemistry in residual breast tumours of patients without a complete pathological response [pCR] (n = 250), from a retrospective cohort of 296 patients treated with anthracycline-based chemotherapy with or without sequential docetaxel prior to surgical resection. SerpinB3 (P = 0.02) and Hsp70 (P = 0.008) positivity in residual tumour were associated with a poor pathological response and serpinB3 was an independent prognostic biomarker (HR 2.1 (95% CI 1.2-3.8), P = 0.02). Docetaxel significantly improved overall survival of breast cancer patients treated with neoadjuvant chemotherapy. Furthermore, serpinB3 positivity predicted poor survival in patients treated with anthracycline-based chemotherapy alone (P = 0.02), but those with serpinB3 negative tumours had as equally good survival as those also treated with docetaxel (P = 0.7). Survival was independent of serpinB3 expression in patients who received sequential docetaxel. The Nottingham prognostic index (NPI), calculated at surgical resection, predicted overall survival in these neoadjuvantly treated patients (P < 0.001) and serpinB3 status segregated patients with a moderate NPI into distinct prognostic subgroups. The use of clinical (NPI) and molecular (serpinB3) biomarkers measured at surgical resection to provide accurate prognostication in patients who do not achieve a pCR following neoadjuvant chemotherapy could facilitate optimal post-operative clinical management of these patients and is of significant clinical value. Furthermore, serpinB3 status in residual tumour is a biomarker of neoadjuvant docetaxel benefit in patients not achieving a pCR and use of serpinB3 molecular subtyping for adjuvant docetaxel treatment planning warrants further investigation.

authors

Collie-Duguid ES,Sweeney K,Stewart KN,Miller ID,Smyth E,Heys SD

doi

10.1007/s10549-011-1625-9

subject

Has Abstract

pub_date

2012-04-01 00:00:00

pages

807-18

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

132

pub_type

杂志文章
  • Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG 16-02).

    abstract:PURPOSE:To evaluate the loco-regional recurrence (LRR) rate after breast-conserving surgery without postoperative radiotherapy (RT) for ductal carcinoma in situ (DCIS) of the breast. METHODS:Between 2000 and 2010, 311 DCIS patients from 9 institutions were analyzed retrospectively. The median age was 47 (range, 20-82)...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-017-4111-1

    authors: Kim K,Jung SY,Shin KH,Kim JH,Han W,Lee HB,Huh SJ,Choi DH,Park W,Ahn SD,Kim SS,Kim JH,Suh CO,Kim YB,Kim IA,Kim S,Kim YJ

    更新日期:2017-02-01 00:00:00

  • Cultured cell lines from human breast cancer biopsies and xenografts.

    abstract::Eighty-five breast cancer specimens were processed as part of a program in tumor acquisition, propagation, and preservation for biotherapy. Nine long-term culture cell lines were developed. Four cell lines were from solid tumor metastases, two lines were from pleural fluid specimens, and three were from xenograft tumo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806292

    authors: Lewko WM,Vaghmar R,Hubbard D,Moore M,He YJ,Chang L,Husseini S,Wallwork K,Thurman GB,Oldham RK

    更新日期:1990-12-01 00:00:00

  • A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family.

    abstract::We report a novel germline 5369delATTT mutation in BRCA2 gene, detected in a 45-year-old woman with bilateral breast cancer. This deletion was also detected in her father with prostatic cancer and her sister with breast cancer. The mutation originates a premature stop at codon 1723 of BRCA2 protein and has not been do...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0361-x

    authors: Salgado J,Aramendía JM,Gutierrez C,Gil C,Robles M,García-Foncillas J

    更新日期:2010-05-01 00:00:00

  • Evaluating breast cancer risk projections for Hispanic women.

    abstract::For Hispanic women, the Breast Cancer Risk Assessment Tool (BCRAT; "Gail Model") combines 1990-1996 breast cancer incidence for Hispanic women with relative risks for breast cancer risk factors from non-Hispanic white (NHW) women. BCRAT risk projections have never been comprehensively evaluated for Hispanic women. We ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1900-9

    authors: Banegas MP,Gail MH,LaCroix A,Thompson B,Martinez ME,Wactawski-Wende J,John EM,Hubbell FA,Yasmeen S,Katki HA

    更新日期:2012-02-01 00:00:00

  • Effect of two-4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer.

    abstract::A number of endocrine treatments for advanced breast cancer seem to affect serum insulin-like growth factor I (IGF-I). The aim of our study was to investigate IGF-I levels in 33 postmenopausal patients with metastatic disease receiving the selective aromatase inhibitor 4-hydroxyandrostenedione: 250 mg (16 patients) or...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00666055

    authors: Ferrari L,Zilembo N,Bajetta E,Buzzoni R,Noberasco C,Martinetti A,Celio L,Galante E,Orefice S,Cerrotta AM

    更新日期:1994-01-01 00:00:00

  • Breast cancer prevention through modulation of endogenous hormones.

    abstract::The use of exogenous sex-steroids for hormonal contraception is important to the way of life of many modern women. The widespread use of hormonal contraceptives represents a unique opportunity to have a substantial positive impact on women's health. The observation that users of oral combination type contraceptives ha...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666430

    authors: Spicer DV,Pike MC

    更新日期:1993-11-01 00:00:00

  • A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.

    abstract::The goal of this study was to compare the efficacy and toxicity of chemotherapy to exemestane plus everolimus (EXE/EVE) through a network meta-analysis (NMA) of randomized controlled trials. NMA methods extend standard pairwise meta-analysis to allow simultaneous comparison of multiple treatments while maintaining ran...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-015-3453-9

    authors: Generali D,Venturini S,Rognoni C,Ciani O,Pusztai L,Loi S,Jerusalem G,Bottini A,Tarricone R

    更新日期:2015-07-01 00:00:00

  • High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.

    abstract::The purpose of the study was to compare breast-conserving therapy (BCT) and mastectomy (M) in BRCA1/2 mutation carriers. Women with invasive breast cancer and a pathogenic mutation in BRCA1 or BRCA2 were included in the study (n = 162). Patients treated with BCT (n = 45) were compared with patients treated with M (n =...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3115-3

    authors: Nilsson MP,Hartman L,Kristoffersson U,Johannsson OT,Borg A,Henriksson K,Lanke E,Olsson H,Loman N

    更新日期:2014-10-01 00:00:00

  • Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells.

    abstract::Proteins can be efficiently introduced into cells when fused to a protein transduction domain, such as Tat from the human immunodeficiency virus. We recently reported that dendritic cells transduced with a Tat fusion protein containing the extracellular domain of Her2/neu (Tat-Her2/neu) induced CD8 cytotoxic T lymphoc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-0450-4

    authors: Viehl CT,Tanaka Y,Chen T,Frey DM,Tran A,Fleming TP,Eberlein TJ,Goedegebuure PS

    更新日期:2005-06-01 00:00:00

  • Breast duct anatomy in the human nipple: three-dimensional patterns and clinical implications.

    abstract:BACKGROUND:The anatomy of the nipple has become clinically relevant. Diagnostic techniques access the breast through nipple ducts and surgeons offer nipple-sparing mastectomy. There is variation in the number of ducts reported and little is known about the spatial location of ducts, their size, and their relationship t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9487-2

    authors: Rusby JE,Brachtel EF,Michaelson JS,Koerner FC,Smith BL

    更新日期:2007-12-01 00:00:00

  • No evidence of human papillomavirus DNA sequences in invasive breast carcinoma.

    abstract::Breast cancer is one of the most frequently diagnosed cancers in women in France, but its aetiology remains unknown. Viruses including Epstein-Barr virus (EBV), a human equivalent of murine mammary tumour virus (MMTV) and human papillomavirus (HPV) have been detected in benign breast tissues and breast tumours and are...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9626-4

    authors: de Cremoux P,Thioux M,Lebigot I,Sigal-Zafrani B,Salmon R,Sastre-Garau X,Institut Curie Breast Group.

    更新日期:2008-05-01 00:00:00

  • Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.

    abstract::Tamoxifen is currently the adjuvant treatment of choice for postmenopausal women with hormone-sensitive breast cancer. However, in the treatment of postmenopausal women with advanced disease, the third-generation aromatase inhibitor anastrozole ('Arimidex') has been shown to be at least as effective as tamoxifen, and ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1025455130476

    authors: Aapro MS,Forbes JF

    更新日期:2003-01-01 00:00:00

  • HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.

    abstract::This retrospective study investigates the correlation of intra-individual HER2 status between primary breast cancers and corresponding recurrences in a population derived cohort. The REMARK criteria were used as reference. In 151 breast cancer patients, primary tumors were analyzed for HER2 status on histopathology se...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1029-2

    authors: Wilking U,Karlsson E,Skoog L,Hatschek T,Lidbrink E,Elmberger G,Johansson H,Lindström L,Bergh J

    更新日期:2011-01-01 00:00:00

  • Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.

    abstract::There remains a high unmet need for effective treatments for metastatic breast cancer. In recent years there have been many advances in the understanding of biological basis of cancer. Several cellular pathways have been identified that play crucial roles in causing or maintaining the cancer phenotype. Many new agents...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-008-0268-y

    authors: Roy V,Perez EA

    更新日期:2009-07-01 00:00:00

  • Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors.

    abstract::Elevated body weight is a risk factor for postmenopausal breast cancer and is associated with increased incidence of spontaneous and chemically induced mammary tumors (MTs) in rodents. In this study, genetically obese Lep(ob)Lep(ob) female mice that overexpress human TGF-alpha (transforming growth factor-alpha) were u...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1021891825399

    authors: Cleary MP,Phillips FC,Getzin SC,Jacobson TL,Jacobson MK,Christensen TA,Juneja SC,Grande JP,Maihle NJ

    更新日期:2003-02-01 00:00:00

  • Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.

    abstract:BACKGROUND:Breakthrough progress has been made in Cyclin-Dependent kinase 4 and 6 (CDK4/6) inhibitors when combined with endocrine therapy (ET) for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Though significant improvements of progression-free survival (PFS) for CDK4/6 inhibitor...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-020-05528-2

    authors: Li J,Fu F,Yu L,Huang M,Lin Y,Mei Q,Lv J,Wang C

    更新日期:2020-02-01 00:00:00

  • CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.

    abstract::Overexpression of CD24 is an independent prognostic factor for breast cancer. Recently, two polymorphisms in the CD24 gene were linked to disease risk and progression in autoimmune diseases. Here, we evaluated the clinical relevance of these polymorphisms with respect to their potential to predict a pathologic complet...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-011-1759-9

    authors: Marmé F,Werft W,Walter A,Keller S,Wang X,Benner A,Burwinkel B,Sinn P,Hug S,Sohn C,Bretz N,Moldenhauer G,Rupp C,Rupp AK,Biakhov MY,Bottini A,Friedrichs K,Khailenko VA,Manikhas GM,Ruiz A,Sánchez-Rovira P,Santoro A

    更新日期:2012-04-01 00:00:00

  • Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.

    abstract::Resistance to tamoxifen is a major clinical challenge in the treatment of breast cancer; however, it is still unclear which signaling pathways are the major drivers of tamoxifen-resistant growth. To characterize resistance mechanisms, we have generated different tamoxifen-resistant breast cancer cell lines from MCF-7....

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2485-2

    authors: Thrane S,Lykkesfeldt AE,Larsen MS,Sorensen BS,Yde CW

    更新日期:2013-05-01 00:00:00

  • CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis.

    abstract::We investigated the expression of -CXC chemokine ligand 13 (CXCL13) and its receptor -CXC chemokine receptor 5 (CXCR5) in 98 breast cancer (BC) patients with infiltrating duct carcinoma, out of which 56 were found lymph node metastasis (LNM) positive. Interestingly, co-expression of CXCL13 and CXCR5 showed a significa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2811-8

    authors: Biswas S,Sengupta S,Roy Chowdhury S,Jana S,Mandal G,Mandal PK,Saha N,Malhotra V,Gupta A,Kuprash DV,Bhattacharyya A

    更新日期:2014-01-01 00:00:00

  • (-)-Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer cells but not of their normal counterparts.

    abstract::(-)-Epigallocatechin (EGC), one of green tea polyphenols, has been shown to inhibit growth of cancer cells. However its mechanism of action is poorly known. We show here that EGC strongly inhibited the growth of breast cancer cell lines (MCF-7 and MDA-MB-231) but not that of normal breast epithelial cells. The inhibit...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1020833410523

    authors: Vergote D,Cren-Olivé C,Chopin V,Toillon RA,Rolando C,Hondermarck H,Le Bourhis X

    更新日期:2002-12-01 00:00:00

  • Factors influencing the use of extended adjuvant endocrine therapy.

    abstract:PURPOSE:Extending adjuvant endocrine therapy (ET) beyond 5 years has been shown to improve outcomes in breast cancer; however, limited data are available about if and why women pursue extended ET. The primary objective was to estimate the proportion of women who were willing to receive extended ET if recommended by the...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05145-8

    authors: Kadakia KC,Kidwell KM,Barton DL,Schott AF,Hayes DF,Griggs JJ,Henry NL

    更新日期:2019-05-01 00:00:00

  • Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.

    abstract::Triple-negative breast cancer is a particularly aggressive and lethal breast cancer subtype that is more likely to be interval-detected rather than screen-detected. The purpose of this study is to discover and initially validate novel early detection biomarkers for triple-negative breast cancer using preclinical sampl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2204-4

    authors: Li CI,Mirus JE,Zhang Y,Ramirez AB,Ladd JJ,Prentice RL,McIntosh MW,Hanash SM,Lampe PD

    更新日期:2012-09-01 00:00:00

  • A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels.

    abstract::In contrast to deoxyribose or arabinose containing nucleoside analogs that are currently established for cancer therapeutics, 8-chloro-adenosine (8-Cl-Ado) possesses a ribose sugar. This unique nucleoside analog is RNA-directed and is in a phase I clinical trial for hematological malignancies. RNA-directed therapies a...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0481-3

    authors: Stellrecht CM,Ayres M,Arya R,Gandhi V

    更新日期:2010-06-01 00:00:00

  • Analyses of microsatellite instability and the transforming growth factor-beta receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features.

    abstract::To determine the incidence of microsatellite instability (MSI) and its relationship with both clinicopathologic parameters and patient survival, 101 cases of breast cancer were investigated. In addition, transforming growth factor-beta (TGF-beta) receptor type II (RII) gene mutation was also examined to clarify the re...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006167210269

    authors: Tomita S,Deguchi S,Miyaguni T,Muto Y,Tamamoto T,Toda T

    更新日期:1999-01-01 00:00:00

  • Survival analysis of censored data: neural network analysis detection of complex interactions between variables.

    abstract::Neural networks can be used as pattern recognition systems in complex data sets. We are exploring their utility in performing survival analysis to predict time to relapse or death. This technique has the potential to find easily some types of very complex interactions in data that would not be easily recognized by con...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00666212

    authors: De Laurentiis M,Ravdin PM

    更新日期:1994-01-01 00:00:00

  • Atypical ezrin localization as a marker of locally advanced breast cancer.

    abstract::Locally advanced breast cancer (LABC) was initially characterized as a large primary tumor (≥5 cm), associated with or without skin or chest-wall involvement, fixed axillary lymph nodes, or disease spread to the ipsilateral internal mammary or supraclavicular nodes. Since 2002, LABC has been reclassified to include sm...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2017-5

    authors: Arslan AA,Silvera D,Arju R,Giashuddin S,Belitskaya-Levy I,Formenti SC,Schneider RJ

    更新日期:2012-08-01 00:00:00

  • Characterization of platelet aggregation induced by human breast carcinoma and its inhibition by snake venom peptides, trigramin and rhodostomin.

    abstract::MCF-7 cells, a metastatic human breast carcinoma line, caused dose-dependent platelet aggregation in heparinized human platelet-rich plasma (PRP). MCF-7 tumor cell-induced platelet aggregation (TCIPA) was almost blocked by apyrase (0.5 U/ml) and completely inhibited by hirudin (5 U/ml). This TCIPA was unaffected by cy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665947

    authors: Chiang HS,Swaim MW,Huang TF

    更新日期:1995-03-01 00:00:00

  • A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer.

    abstract::To date, three molecular markers (ER, PR, and CYP2D6) have been used in clinical setting to predict the benefit of the anti-estrogen tamoxifen therapy. Our aim was to validate new biomarker candidates predicting response to tamoxifen treatment in breast cancer by evaluating these in a meta-analysis of available transc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-013-2622-y

    authors: Mihály Z,Kormos M,Lánczky A,Dank M,Budczies J,Szász MA,Győrffy B

    更新日期:2013-07-01 00:00:00

  • HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.

    abstract::The proto-oncogene, HER2, has prognostic and predictive relevance in invasive breast cancer (IBC). HER2 testing of primary IBC guides treatment selection and is assumed to reflect HER2 status of associated metastases, although HER2 discordance between IBC and metastasis has been reported. Systematic review and meta-an...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-011-1632-x

    authors: Houssami N,Macaskill P,Balleine RL,Bilous M,Pegram MD

    更新日期:2011-10-01 00:00:00

  • Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.

    abstract:PURPOSE:Peripheral blood lymphopenia and elevated neutrophil-to-lymphocyte ratio (NLR) have been associated with poor outcomes in various malignancies. However, existing literature has largely focused on baseline parameters. The aim of this study is to assess the impact of radiation therapy (RT) and chemotherapy on abs...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05106-7

    authors: Patel DA,Xi J,Luo J,Hassan B,Thomas S,Ma CX,Campian JL

    更新日期:2019-04-01 00:00:00